NewLink Genetics Corporation Company Profile (NASDAQ:NLNK)

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NLNK
  • CUSIP: 65151110
  • Web: www.newlinkgenetics.com
Capitalization:
  • Market Cap: $213.05 million
  • Outstanding Shares: 29,225,000
Average Prices:
  • 50 Day Moving Avg: $12.84
  • 200 Day Moving Avg: $14.67
  • 52 Week Range: $5.90 - $25.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.86
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $32.82 million
  • Price / Sales: 6.49
  • Book Value: $3.91 per share
  • Price / Book: 1.86
Profitability:
  • EBIDTA: ($73,110,000.00)
  • Net Margins: -250.91%
  • Return on Equity: -61.98%
  • Return on Assets: -47.73%
Debt:
  • Current Ratio: 5.12%
  • Quick Ratio: 5.12%
Misc:
  • Average Volume: 973,741 shs.
  • Beta: 1.35
  • Short Ratio: 7.49
 

Frequently Asked Questions for NewLink Genetics Corporation (NASDAQ:NLNK)

What is NewLink Genetics Corporation's stock symbol?

NewLink Genetics Corporation trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics Corporation's earnings last quarter?

NewLink Genetics Corporation (NASDAQ:NLNK) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.10. The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $2.68 million. NewLink Genetics Corporation had a negative net margin of 250.91% and a negative return on equity of 61.98%. View NewLink Genetics Corporation's Earnings History.

Where is NewLink Genetics Corporation's stock going? Where will NewLink Genetics Corporation's stock price be in 2017?

5 analysts have issued twelve-month target prices for NewLink Genetics Corporation's stock. Their predictions range from $8.00 to $32.00. On average, they anticipate NewLink Genetics Corporation's stock price to reach $22.80 in the next year. View Analyst Ratings for NewLink Genetics Corporation.

What are analysts saying about NewLink Genetics Corporation stock?

Here are some recent quotes from research analysts about NewLink Genetics Corporation stock:

  • 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (6/9/2017)
  • 2. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
  • 3. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Who are some of NewLink Genetics Corporation's key competitors?

Who are NewLink Genetics Corporation's key executives?

NewLink Genetics Corporation's management team includes the folowing people:

  • Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
  • Nicholas N. Vahanian M.D., President, Chief Medical Officer, Director
  • John Bell Henneman III, Chief Financial Officer, Secretary
  • Brian Wiley, Chief Commercial Officer
  • Thomas A. Raffin M.D., Lead Independent Director
  • Paolo Pucci, Director
  • Paul R. Edick, Independent Director
  • Joseph B. Saluri, Independent Director
  • Ernest J. Talarico III, Independent Director

Who owns NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.29%), FMR LLC (3.10%), Columbus Circle Investors (1.17%), Driehaus Capital Management LLC (0.73%), Teachers Advisors LLC (0.71%) and Bank of New York Mellon Corp (0.69%). Company insiders that own NewLink Genetics Corporation stock include Brian Wiley, Carl W Langren, Charles J Jr Link, John B Henneman III and Joseph Saluri. View Institutional Ownership Trends for NewLink Genetics Corporation.

Who sold NewLink Genetics Corporation stock? Who is selling NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, TFS Capital LLC, Morgan Stanley, Piermont Capital Management Inc., Trexquant Investment LP, Alliancebernstein L.P. and Credit Suisse AG. View Insider Buying and Selling for NewLink Genetics Corporation.

Who bought NewLink Genetics Corporation stock? Who is buying NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Columbus Circle Investors, EAM Investors LLC, Ameriprise Financial Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Bank of New York Mellon Corp and Endurant Capital Management LP. View Insider Buying and Selling for NewLink Genetics Corporation.

How do I buy NewLink Genetics Corporation stock?

Shares of NewLink Genetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics Corporation's stock price today?

One share of NewLink Genetics Corporation stock can currently be purchased for approximately $7.29.


MarketBeat Community Rating for NewLink Genetics Corporation (NASDAQ NLNK)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NewLink Genetics Corporation (NASDAQ:NLNK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $22.80 (212.76% upside)

Analysts' Ratings History for NewLink Genetics Corporation (NASDAQ:NLNK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Robert W. BairdDowngradeOutperform -> Neutral$25.00 -> $8.00HighView Rating Details
6/4/2017Cantor FitzgeraldSet Price TargetBuy$32.00HighView Rating Details
5/15/2017Jefferies Group LLCReiterated RatingHold$18.00MediumView Rating Details
4/22/2017Stifel NicolausReiterated RatingBuy$26.00MediumView Rating Details
3/30/2017SunTrust Banks, Inc.UpgradeHold -> Buy$12.00 -> $30.00HighView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 6/28/2015 forward)

Earnings

Earnings History for NewLink Genetics Corporation (NASDAQ:NLNK)
Earnings by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Earnings History by Quarter for NewLink Genetics Corporation (NASDAQ NLNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.46)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)ViewN/AView Earnings Details
11/11/2013Q3($0.33)($0.32)ViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.23 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)
2017 EPS Consensus Estimate: ($2.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20172($0.82)($0.71)($0.77)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NewLink Genetics Corporation (NASDAQ:NLNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NewLink Genetics Corporation (NASDAQ:NLNK)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 51.52%
Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.05View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.15View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.50View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NewLink Genetics Corporation (NASDAQ:NLNK)
Latest Headlines for NewLink Genetics Corporation (NASDAQ:NLNK)
Source:
DateHeadline
americanbankingnews.com logo$2.65 Million in Sales Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - June 28 at 12:08 PM
americanbankingnews.com logoZacks: Brokerages Expect NewLink Genetics Corporation (NLNK) Will Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - June 26 at 8:34 AM
streetinsider.com logoNewLink Genetics (NLNK) Presents Positive Phase 1b Data for IDO ... - StreetInsider.com
www.streetinsider.com - June 24 at 12:23 AM
finance.yahoo.com logoPositive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain
finance.yahoo.com - June 23 at 8:26 AM
fool.com logoThese 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
www.fool.com - June 21 at 4:30 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in NewLink (NLNK) Stock?
finance.yahoo.com - June 13 at 6:56 PM
americanbankingnews.com logoQ2 2017 Earnings Forecast for NewLink Genetics Corporation (NLNK) Issued By Jefferies Group
www.americanbankingnews.com - June 12 at 7:10 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - June 11 at 10:56 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - June 10 at 2:26 PM
finance.yahoo.com logoRoche-NewLink Drug Move Shouldn't Impact Incyte, Says Analyst
finance.yahoo.com - June 9 at 7:05 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - June 9 at 3:22 PM
nasdaq.com logoD-Day For CHRS, ENDP Pained, FDA Lifts Clinical Hold On INO's VGX-3100 Trial - Nasdaq
www.nasdaq.com - June 9 at 12:44 AM
finance.yahoo.com logoNewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate
finance.yahoo.com - June 8 at 7:43 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Cut to "Neutral" at Robert W. Baird
www.americanbankingnews.com - June 8 at 12:22 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Nordstrom, Alibaba, Urban Outfitters - Nasdaq
www.nasdaq.com - June 8 at 9:52 AM
marketwatch.com logoNewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate - MarketWatch
www.marketwatch.com - June 8 at 9:52 AM
feeds.benzinga.com logoNewLink Genetics to Regain Rights to GDC-0919
feeds.benzinga.com - June 8 at 7:15 AM
americanbankingnews.com logoRobert W. Baird Reiterates Outperform Rating for NewLink Genetics Corp (NLNK)
www.americanbankingnews.com - June 5 at 10:00 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) PT Set at $32.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 5 at 8:42 PM
finance.yahoo.com logoNewLink Genetics’ Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial
finance.yahoo.com - June 5 at 7:29 PM
nasdaq.com logoAMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce - Nasdaq
www.nasdaq.com - June 5 at 8:55 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 5 at 8:50 AM
streetinsider.com logoNewLink Genetics (NLNK) Phase 2 trial of Indoximod in Combination with Taxane Doesn't Meet Endpoints
www.streetinsider.com - June 3 at 6:23 PM
finance.yahoo.com logoResults from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
finance.yahoo.com - June 2 at 9:11 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.65 Million
www.americanbankingnews.com - June 2 at 3:24 PM
americanbankingnews.com logo-$0.78 Earnings Per Share Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - May 31 at 9:18 AM
finance.yahoo.com logoUpdate in Lawsuit for Investors in NewLink Genetics Corp (NASDAQ: NLNK) Shares Announced by Shareholders Foundation
finance.yahoo.com - May 30 at 6:31 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 29 at 9:30 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Upgraded at ValuEngine
www.americanbankingnews.com - May 19 at 3:28 PM
streetinsider.com logoNewLink Genetics (NLNK) Says Data from Clinical Study of Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at EHA
www.streetinsider.com - May 19 at 11:37 AM
finance.yahoo.com logoBiotech Stocks: Is ASCO Much Ado About Nothing?
finance.yahoo.com - May 19 at 11:37 AM
finance.yahoo.com logoData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
finance.yahoo.com - May 18 at 8:08 AM
feeds.benzinga.com logoData from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
feeds.benzinga.com - May 18 at 7:33 AM
streetinsider.com logoNewLink Genetics (NLNK) Says Data from Studies of Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO
www.streetinsider.com - May 17 at 11:48 PM
finance.yahoo.com logoData from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
finance.yahoo.com - May 17 at 6:47 PM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK - Business Wire (press release)
www.businesswire.com - May 16 at 10:13 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK
finance.yahoo.com - May 16 at 10:13 AM
americanbankingnews.com logoZacks Investment Research Upgrades NewLink Genetics Corp (NLNK) to Hold
www.americanbankingnews.com - May 14 at 9:32 PM
americanbankingnews.com logoShort Interest in NewLink Genetics Corp (NLNK) Rises By 31.5%
www.americanbankingnews.com - May 13 at 7:20 AM
247wallst.com logoHow Ebola Stocks Are Responding After the Outbreak in the Congo
247wallst.com - May 12 at 7:29 PM
americanbankingnews.com logoNewLink Genetics Corp Forecasted to Earn FY2017 Earnings of ($2.53) Per Share (NLNK)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to NewLink Genetics Corp. : May 11, 2017
finance.yahoo.com - May 11 at 7:21 PM
finance.yahoo.com logoNewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 11:32 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 9 at 9:02 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Announces Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - May 8 at 7:32 PM
finance.yahoo.com logoNewLink Genetics to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 8 at 12:18 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given a $32.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 7 at 7:34 AM
seekingalpha.com logoNewLink Genetics' (NLNK) CEO Charles Link on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 6 at 12:09 AM
feeds.benzinga.com logoMid-Afternoon Market Update: California Resources Surges On Earnings Beat; ArcBest Shares Slide
feeds.benzinga.com - May 5 at 3:16 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Receives "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 5 at 12:14 PM

Social

Chart

NewLink Genetics Corporation (NLNK) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by MarketBeat.com Staff